Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oric Pharmaceuticals (ORIC)
NASDAQ:ORIC
RESEARCH TOOLSreports
Oric Pharmaceuticals (ORIC) Stock Price & Analysis
278 Followers
ORIC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.27 - $16.65
Previous Close$10.69
Volume418.69K
Average Volume (3M)557.65K
Market Cap
$720.74M
Enterprise Value$403.97M
Total Cash (Recent Filing)$316.78M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Aug 08, 2024EPS Estimate
-$0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.81
Shares Outstanding67,422,307
10 Day Avg. Volume417,192
30 Day Avg. Volume557,649
Standard Deviation0.25
R-Squared0.06
Alpha-0.00889
Financial Highlights & Ratios
Price to Book (P/B)2.18
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.64
Forecast
1Y Price Target
$19.33Price Target Upside71.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Oric Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe monotherapy data showed low variability between patients, and no signs of CYP autoinduction.
Drug Development ProgressInitial Phase 1b PK/PD data for ORIC-944 showed favorable drug properties.
Financial HealthORIC ended the quarter with substantial cash reserves, supporting its operations and development programs well into the future.
Bears Say
Clinical Development RisksRisks include, but are not limited to: inability to advance ORIC-533, ORIC-114 and ORIC-944 in clinical development; negative clinical data with these pipeline candidates; delays in moving into pivotal clinical trials.
Clinical Trialsour doc doesn't like to stack enza directly following abiraterone, based on poorer PFS data than following with chemo
Study Design Concernsnot totally confident whether the study will be powered for statistical significance (each arm is ≤40 patients)
---
Ownership Overview
22.23% Insiders
15.14% Mutual Funds
11.53% Other Institutional Investors
51.10% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ORIC FAQ
What was Oric Pharmaceuticals’s price range in the past 12 months?
Oric Pharmaceuticals lowest stock price was $5.27 and its highest was $16.65 in the past 12 months.
What is Oric Pharmaceuticals’s market cap?
Currently, no data Available
When is Oric Pharmaceuticals’s upcoming earnings report date?
Oric Pharmaceuticals’s upcoming earnings report date is Aug 08, 2024 which is in 15 days.
How were Oric Pharmaceuticals’s earnings last quarter?
Oric Pharmaceuticals released its earnings results on May 06, 2024. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.429 by $0.059.
Is Oric Pharmaceuticals overvalued?
According to Wall Street analysts Oric Pharmaceuticals’s price is currently Undervalued.
Does Oric Pharmaceuticals pay dividends?
Oric Pharmaceuticals does not currently pay dividends.
What is Oric Pharmaceuticals’s EPS estimate?
Oric Pharmaceuticals’s EPS estimate is -$0.41.
How many shares outstanding does Oric Pharmaceuticals have?
Oric Pharmaceuticals has 67,422,310 shares outstanding.
What happened to Oric Pharmaceuticals’s price movement after its last earnings report?
Oric Pharmaceuticals reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.429. Following the earnings report the stock price went up 2.561%.
Which hedge fund is a major shareholder of Oric Pharmaceuticals?
Among the largest hedge funds holding Oric Pharmaceuticals’s share is Viking Global Investors LP. It holds Oric Pharmaceuticals’s shares valued at 55M.
---
Oric Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.33 (71.67% Upside)
$19.33 (71.67% Upside)
Blogger Sentiment
Bullish
ORIC Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 4.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
24.59%
12-Months-Change
Fundamentals
Return on Equity
-38.30%
Trailing 12-Months
Asset Growth
54.77%
Trailing 12-Months
Company Description
Oric Pharmaceuticals
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101 and ORIC-533.
---
ORIC Stock 12 Month Forecast
Average Price Target
$19.33
▲(71.67% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Arvinas Holding Company
―
Crispr Therapeutics AG
―
MacroGenics
―
Best Analysts Covering ORIC
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
+23.65%
reiterated a buy rating 3 months ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +23.65% per trade.
---